Ivosidenib with ruxolitinib for advanced MPN with IDH1 mutation
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a combination of two targeted drugs, ivosidenib and ruxolitinib, for people with advanced myeloproliferative neoplasms (MPNs) that have an IDH1 gene mutation. The goal is to see if this treatment can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced MPN (like myelofibrosis, polycythemia vera, or others) that has an IDH1 gene mutation.
- Your disease has at least 5% blasts (immature cells) in your blood or bone marrow, or you have myelofibrosis that did not respond well to a JAK inhibitor.
- You are 18 years or older.
- You are not pregnant and agree to use effective birth control if needed.
- Your kidneys and liver are working well enough, and you have a platelet count of at least 50,000 if you have chronic-phase myelofibrosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, INCA033989, alone or with ruxolitinib for people with certain blood cancers called myeloproliferative neoplasms (MPNs). It may help those with a specific genetic change (CALR mutation) who have not had success with other treatments.
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
Hear when a new Myeloproliferative Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.